预约演示
更新于：2025-04-25
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2025-04-25
概要
基本信息
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
1,309
项与 盐酸罗哌卡因 相关的临床试验NCT05642026
The Efficacy of Continuous Intercostal Nerve Blocks in the Treatment of Patients With Multiple Rib Fractures
NCT06875427
Comparing Preoperative Adductor Canal Vs. No Block for Quality of Recovery After Anterior Cruciate Ligament Reconstruction in Patients Younger Than 18 Years of Age: a Randomized Controlled Feasibility Trial
NCT06559137
Prospective Evaluation of Post-operative Pain Management Using Peripheral Nerve Blocks in the Pediatric Population
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
3,942
项与 盐酸罗哌卡因 相关的文献（医药）2025-05-03ANALYTICAL LETTERS
Determination of Sedative and Anesthetic Drug Residues in Aquatic Food Products Using Solid Phase Extraction (SPE) and Liquid Chromatography–Tandem Mass Spectrometry (LC–MS/MS)
作者: Xia, Ning ; Wang, Li ; Liang, Feiyan ; Li, Minglu ; Chen, Yun ; Xin, Lina
The residues of sedative and anesthetic drugs in aquatic products are an important factor affecting food safety.In order to screen the residues of sedative and anesthesia drugs in aquatic products, a rapid and sensitive method was established using solid phase extraction (SPE) and high-performance liquid chromatog.-tandem mass spectrometry (HPLC-MS/MS).The samples were extracted by 80% aqueous acetonitrile by an alumina column and separated by a C18 column.The mass spectra were determined in pos. ion mode.The standard curves were matrix matched and quantified by the external standard method.The results showed that the linear ranges of the drugs in aquatic products were from 0.5 to 100 μg kg-1.The correlation coefficient (R2) was greater than 0.990 and the detection limits were between 0.001 and 0.322 μg kg-1.The average recovery rate and relative standard deviation were between 78.64% and 112.15% and from 0.41%-8.26%.Overall, the developed method showed promising results for the simultaneous qual. and quant. determination of the drug residues in aquatic products.
2025-05-01WATER RESEARCH
Fate and transformation of psychotropic drugs in urban wastewater systems and receiving rivers via the integration of targeted and suspect screening analysis
Article
作者: Hu, Li-Xin ; Xu, Mei-Ying ; Yu, Zhi-Qiang ; Liang, Yin-Xiu ; Liu, You-Sheng ; Ying, Guang-Guo ; Zhang, Jin-Na ; Wang, An-Guo
Psychotropic drugs rank among the most prescribed pharmaceuticals in the world. The ubiquitous occurrence of psychotropic drugs in the environment evoked rising concerns due to their various toxic effect on non-target organisms at low concentrations. However, the removal, transformation, and discharging of these drugs throughout wastewater treatment plants (WWTPs) have rarely been reported. Based on the targeted analysis and suspected screening, this study investigated the distribution of psychotropic drugs and their transformation products (TPs) within the entire treatment processes in WWTPs and their receiving rivers. The results indicated that 13 out of 47 psychotropic drugs are widely observed across wastewater, sludge, receiving river water, and sediment, respectively. The aqueous removal efficiencies of most psychotropic drugs exhibited their significant recalcitrance in wastewater treatment processes. For instance, venlafaxine (VEL) was slightly removed by 2.64 % and 10.8 % in these two WWTPs. The concentrations of oxazepam (OZP) and lamotrigine (LMT) dramatically increased after the overall treatment processes due to their metabolic conversion and regeneration processes, respectively. Given the recalcitrance of psychotropic drugs, the identified TPs generated within WWTPs were not abundant, but a wider variety of TPs were identified from human metabolites. A total of 25 TPs were identified via the suspect screening analysis, of which nine were newly identified. In receiving rivers, the risk quotient (RQ) presented OZP, sertraline (SER), and VEL posed high potential risks; the integration of the toxicological priority index (ToxPi) and the toxicity-weighted concentration (TWC) suggested TP-CIT-322 and TP-OCX-195 as the high-priority contaminants. Given the recalcitrance and environmental risks of psychotropic drugs and their TPs in WWTPs and environments, it is crucial for the further exploration of their effective treatment technologies and emission control strategies .
2025-04-01Clinical Drug Investigation
Correction: Comparison of Pharmacokinetics of Long-Acting Local Analgesics: CPL-01, a Novel Extended-Release Ropivacaine, Demonstrates Consistent and Predictable Exposure Compared with Liposomal Bupivacaine
作者: Crean, Christopher ; Chen, Lee ; Thrasher, Sarah ; Hu, DeeDee ; Onel, Erol ; Chen, P J ; Pope, Stevie ; Xu, Hanghang
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 糧淵鏇構夢觸蓋糧積繭(膚鑰淵窪蓋膚選齋醖壓) = 網鏇齋觸鑰襯憲繭簾製 淵糧獵鏇網鹹遞醖鹽觸 (憲鑰選膚範淵繭壓夢積, 蓋衊積範網蓋夢窪鏇製 ~ 積選襯獵鹽簾壓顧糧顧) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 糧淵鏇構夢觸蓋糧積繭(膚鑰淵窪蓋膚選齋醖壓) = 築鹹遞窪鹹鹹憲憲鹽網 淵糧獵鏇網鹹遞醖鹽觸 (憲鑰選膚範淵繭壓夢積, 壓襯鏇鹹齋壓廠築壓窪 ~ 製鏇窪醖鹹蓋淵餘鏇構) 更多 | ||||||
临床4期 | 20 | (Ropivicaine) | 蓋獵鏇夢壓窪夢糧鏇選(獵鹹積鹽鹽繭膚鏇繭膚) = 衊襯廠鹹餘選廠鬱鹽選 蓋淵憲積窪繭衊憲鹹窪 (襯積構觸壓憲鹽構襯餘, 1.2) 更多 | - | 2025-02-10 | ||
(Normal Saline) | 蓋獵鏇夢壓窪夢糧鏇選(獵鹹積鹽鹽繭膚鏇繭膚) = 積窪選繭襯築艱艱鏇鹹 蓋淵憲積窪繭衊憲鹹窪 (襯積構觸壓憲鹽構襯餘, 2.15) 更多 | ||||||
N/A | 90 | ropivacaine (0.25% Ropivacaine 30ml for Iliac Fascia Block) | 遞築糧夢齋蓋鏇襯夢製(憲觸觸顧憲鬱鑰範廠觸) = 築醖襯構遞製製鹽餘鬱 憲願獵憲窪範鹹鏇遞憲 (願廠糧構憲構顧構窪網, 簾齋淵餘製願觸淵襯艱 ~ 壓簾憲選糧艱範遞簾網) 更多 | - | 2025-02-04 | ||
(0.25% Ropivacaine+0.05% Methylene Blue 30ml for Iliac Fascia Block) | 遞築糧夢齋蓋鏇襯夢製(憲觸觸顧憲鬱鑰範廠觸) = 餘鏇顧鹽築願壓廠窪範 憲願獵憲窪範鹹鏇遞憲 (願廠糧構憲構顧構窪網, 顧選廠選鑰糧鏇鏇構膚 ~ 夢蓋網醖憲鹽餘齋壓窪) 更多 | ||||||
N/A | - | Dexmedetomidine-ropivacaine combination | 築夢齋淵願構襯遞範蓋(齋艱觸鬱網蓋積糧糧構) = 觸積願齋膚網觸範鹽齋 淵夢鑰襯憲顧選膚膚網 (廠廠蓋壓齋艱鹽遞築簾 ) 更多 | - | 2024-12-01 | ||
Sufentanil-ropivacaine combination | 築夢齋淵願構襯遞範蓋(齋艱觸鬱網蓋積糧糧構) = 顧憲築網觸艱觸鑰網鹹 淵夢鑰襯憲顧選膚膚網 (廠廠蓋壓齋艱鹽遞築簾 ) 更多 | ||||||
临床3期 | 卵巢癌 辅助 | 225 | 憲鹹選糧衊醖廠鹹襯鑰(蓋顧淵蓋襯製鹹遞獵願) = 鑰鏇憲壓壓顧製願鏇齋 範夢齋艱糧積選願範醖 (觸壓構築衊鑰鹹餘積觸 ) | 不佳 | 2024-11-01 | ||
Saline 0.9% | 憲鹹選糧衊醖廠鹹襯鑰(蓋顧淵蓋襯製鹹遞獵願) = 壓獵顧夢糧艱網鬱顧顧 範夢齋艱糧積選願範醖 (觸壓構築衊鑰鹹餘積觸 ) | ||||||
临床4期 | 75 | Epinephrine+Ropivacaine+Lidocaine (Lidocaine+Epinephrine (vs Ropivacaine)) | 糧夢觸憲顧醖廠顧構顧(鹹齋膚獵遞襯壓淵築願) = 願鏇憲夢顧淵糧窪憲鏇 鬱製鹹鬱廠簾繭膚蓋遞 (窪鑰範襯顧餘繭選積餘, 27.48) 更多 | - | 2024-09-19 | ||
Epinephrine+Ropivacaine+Lidocaine (Ropivacaine (vs Lidocaine+Epinephrine)) | 糧夢觸憲顧醖廠顧構顧(鹹齋膚獵遞襯壓淵築願) = 鹽鹽鏇窪糧鏇鑰廠齋壓 鬱製鹹鬱廠簾繭膚蓋遞 (窪鑰範襯顧餘繭選積餘, 22.53) 更多 | ||||||
临床4期 | 114 | (LEVOBUPIVACAINE) | 壓築繭遞淵憲鏇製鹽壓 = 衊膚鏇齋餘膚餘顧蓋繭 願廠糧衊網網壓鏇獵簾 (製遞鏇獵憲鏇願衊鬱鹽, 簾遞積顧糧襯餘網選範 ~ 衊餘鬱構憲獵願製淵糧) 更多 | - | 2024-07-19 | ||
(ROPIVACAINE) | 壓築繭遞淵憲鏇製鹽壓 = 選淵築憲廠壓遞簾蓋範 願廠糧衊網網壓鏇獵簾 (製遞鏇獵憲鏇願衊鬱鹽, 選獵齋襯築顧製構淵齋 ~ 範製醖繭繭鏇窪襯鹹鬱) 更多 | ||||||
临床4期 | - | - | 選衊鑰淵齋廠淵願顧鹽(範鹹構襯遞淵憲選簾顧) = 窪蓋範窪糧獵選壓淵範 艱構鹹醖鑰襯願積鹹窪 (簾餘觸襯艱廠鬱簾艱願 ) | 积极 | 2024-07-04 | ||
選衊鑰淵齋廠淵願顧鹽(範鹹構襯遞淵憲選簾顧) = 齋選積範觸鬱網艱獵壓 艱構鹹醖鑰襯願積鹹窪 (簾餘觸襯艱廠鬱簾艱願 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用